Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Dermatol. 2006 Jan;142(1):37-41.

Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy.

Author information

  • 1Eastern Virginia Medical School, Norfolk, USA.

Abstract

OBJECTIVE:

To examine whether patients had received bisphosphonates at the beginning of planned long-term glucocorticoid therapy, which is recommended by the guidelines from the American College of Rheumatology to prevent glucocorticoid-induced osteoporosis, prior to referral to a tertiary dermatology clinic.

DESIGN:

Cross-sectional study.

SETTING:

Tertiary referral center.

PATIENTS:

We reviewed 35 patients from an established cohort of patients referred with chronic skin diseases that require prolonged glucocorticoid use.

MAIN OUTCOME MEASURE:

The use of osteoporosis prophylaxis was determined by medical chart review and communication with patients.

RESULTS:

Of 35 patients, 28 (80%) were not receiving any bisphosphonates at referral. These patients began glucocorticoid therapy 17 months (median, 6 months; range, 1-102 months) prior to referral. The proportion of patients treated with bisphosphonates in our cohort did not change after the guidelines of the American College of Rheumatology were published.

CONCLUSIONS:

For patients of non-child-bearing potential with dermatological diseases in which prolonged oral corticosteroid treatment is anticipated, bisphosphonates should be prescribed concomitantly with the initiation of glucocorticoid therapy.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Write to the Help Desk